Allopurinol as a possible new therapy for acute coronary syndromes: The Next Steps - ALL ACS- (ALLOPURINOL IN ACUTE CORONARY SYNDROME)

niversity of Dundee0 个研究点开始时间: 2011年11月28日最近更新: 2017年4月3日

适应症

试验速览

暂无简介。

•Age 18-85 male or female. angiographically documented coronary artery disease, a positive exercise tolerance test (ETT) a history of symptoms of chronic, stable, effort-induced angina for = 2 months. All concomitant antianginal medication will be allowed and continued unchanged during the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 26

•Exclusion criteria will include •the inability to do an ETT due to back or leg problems, •myocardial infarction or acute coronary syndrome = 2 months, •coronary revascularization (percutaneous or CABG) = 6 months, •Left Ventricular Ejection Fraction <45%, •estimated GFR <60 ml/min or creatinine >180 mmol/ml, •significant valvular pathology, •already had gout or on allopurinol, •atrial arrhythmias or ECG abnormalities interfering with ST-segment interpretation, •previous ventricular arrhythmias on ETT, •severe hepatic disease •or on azathioprine, 6 mercaptopurine or warfarin. •Patients who have participated in any other clinical trial within the previous 30 days will be excluded. •Patients who are unable to give informed consent will also be excluded from this trial.

发起方

niversity of Dundee